Skip to main content

Table 1 Patient characteristics

From: Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes

Variable No. (%) or
Median (Range)
Age, years 68 (50–85)
Race and ethnicity
 African-American 3 (1.6%)
 Asian 4 (2.1%)
 Hispanic 2 (1.0%)
 White 176 (91.7%)
 Unknown 7 (3.6%)
T stage
 T1 104 (54.2%)
 T2a 49 (25.5%)
 T2b 25 (13.0%)
 T2c 4 (2.1%)
 T3-T4 10 (5.2%)
PSA, ng/ml 7.2 (1.6–69.6)
Gleason score
 6 42 (21.9%)
 7 = 3 + 4 80 (41.7%)
 7 = 4 + 3 36 (18.8%)
 8 14 (7.3%)
 9–10 20 (10.4%)
Risk category
 Low 38 (19.8%)
 Intermediate 104 (54.2%)
 High 50 (26.0%)
Baseline IPSS Bother scorea 2 (0–7)
Baseline IPSS scorea 6 (0–28)
Baseline EPIC bowel domain scorea 96 (61–100)
Baseline SHIM scoreab 18 (0–25)
Comorbidities
 History of diabetes 19 (9.9%)
 History of hypertension 96 (50.0%)
 History of inflammatory bowel disease 2 (1.0)
 History of hemorrhoids 26 (13.5%)
Smoking statusa
 Never 103 (57.5%)
 Former 65 (36.3%)
 Current 11 (6.1%)
Aspirin use 74 (38.5%)
Anticoagulant use 22 (11.5%)
Pre-treatment urologic function
 Alpha blocker use 37 (19.3%)
 Alpha reductase inhibitor use 14 (7.3%)
 TURP 9 (4.7%)
Androgen deprivation therapy 71 (37.0%)
 Low risk 1/71 (1.4%)
 Intermediate risk 27/71 (38.0%)
 High risk 43/71 (60.6%)
Pencil beam vs. uniform scanning 144 vs 48 (75.0% vs 25%)
Number of fields/day
 1 92 (48%)
 2 100 (52%)
Whole pelvis radiation 19 (9.9%)
US-based prostate volume, cm3 40 (12–100)
  1. aThose with missing values were excluded from the corresponding summary: IPSS bother score (n = 7), IPSS score (n = 4), EPIC score (n = 28), SHIM score (n = 14), smoking status (n = 13), and US-based prostate volume (n = 12);
  2. bBased on patients not receiving androgen deprivation therapy (n = 121)